Trials / Completed
CompletedNCT00486291
Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics
A Phase 2, Randomized, Double Blind, Parallel Design Study Comparing the Efficacy and Safety of VI-0521 to Placebo in the Glycemic Management of Obese Diabetic Adults
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 210 (actual)
- Sponsor
- VIVUS LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of VI-0521 compared to placebo in the glycemic management of obese diabetic adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VI-0521 | phentermine 15mg/topiramate 100mg |
| DRUG | Placebo | matched placebo |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2007-06-14
- Last updated
- 2012-09-10
- Results posted
- 2012-09-03
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00486291. Inclusion in this directory is not an endorsement.